VIDEO: Novel therapies show promise for patients with bladder, kidney cancer

In this video, Russell K. Pachynski, MD, assistant professor at Washington University School of Medicine in St. Louis, discusses the results of updated efficacy data presented at the ASCO Annual Meeting.

The IMvigor 210 trial demonstrated that patients who were platinum ineligible – as well as those who had progressed on platinum – had good response rates after treatment with atezolizumab (Tecentriq, Genentech/Roche).

“One of the important things to note is the duration of these responses were quite long,” Pachynski said. “In fact, there were late conversions from partial response to complete response. So that’s important to know when you’re treating these patients with atezolizumab, that you may have a delayed and durable response.”

Pachynski also highlights an additional novel therapy — pegylated IL-10. Patients with renal cell carcinoma demonstrated a 50% overall response rate and a disease control rate of 100% after treatment with pegylated IL-10.

“With immunotherapy, these responses have been durable, and so we expect to see more and longer responses,” he said. This is a promising new therapy that is continuing in development.”